Science and Technology Committee, scrutiny, Antimicrobial resistance, AMR
Evidence hearing - Antimicrobial resistance (AMR)
2 January 2014
This is the second evidence session of the inquiry.
The first panel will answer questions regarding clinical practice relating to antimicrobial resistance. Topics covered will include the education of healthcare professionals, prescribing practices, diagnostics, public awareness and community infections.
The second panel will provide evidence on different approaches to address infection that may help with the issue of anti-microbial resistance, including bacteriophages, vaccines, alternative medicines and diagnostics.
Evidence hearing
Wednesday 8 January 2014
Thatcher Room, Portcullis House
At 9.15 am
- Professor Anthony Kessel, Director of Public Health Strategy, Director of R&D and Responsible Officer, Public Health England
- Dr Michael Moore, National Clinical Champion for Antimicrobial Stewardship, Royal College of General Practitioners
- Professor Alison Holmes, Director of Infection Prevention and Control, National Centre for Infection Prevention and Management, Imperial College London
- Dr Susan Hopkins, Chair, Healthcare Associated Infections Working Group, Royal College of Physicians
At 10.15 am
- John Hardcastle, Chief Executive Officer, Novolytics
- Dr David McIntosh, Global Scientific Affairs Senior Expert, Novartis
- Professor George Lewith, Professor of Health Research, University of Southampton Medical School
- Doris-Ann Williams, Chief Executive, British In Vitro Diagnostics Association (BIVDA)
Further evidence sessions will be announced in due course.